KR102374500B1 - 바이오프테린 유도체를 포함하는 고체 약제학적 조성물 및 이러한 조성물의 용도 - Google Patents

바이오프테린 유도체를 포함하는 고체 약제학적 조성물 및 이러한 조성물의 용도 Download PDF

Info

Publication number
KR102374500B1
KR102374500B1 KR1020167025896A KR20167025896A KR102374500B1 KR 102374500 B1 KR102374500 B1 KR 102374500B1 KR 1020167025896 A KR1020167025896 A KR 1020167025896A KR 20167025896 A KR20167025896 A KR 20167025896A KR 102374500 B1 KR102374500 B1 KR 102374500B1
Authority
KR
South Korea
Prior art keywords
compound
formula
hpo
biopterin
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167025896A
Other languages
English (en)
Korean (ko)
Other versions
KR20160138406A (ko
Inventor
피터 슐러
프랭크 테그트마이어
라인하르트 쉰젤
Original Assignee
바조팜 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바조팜 게엠베하 filed Critical 바조팜 게엠베하
Publication of KR20160138406A publication Critical patent/KR20160138406A/ko
Application granted granted Critical
Publication of KR102374500B1 publication Critical patent/KR102374500B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167025896A 2014-03-31 2015-03-30 바이오프테린 유도체를 포함하는 고체 약제학적 조성물 및 이러한 조성물의 용도 Active KR102374500B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162727.3 2014-03-31
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (2)

Publication Number Publication Date
KR20160138406A KR20160138406A (ko) 2016-12-05
KR102374500B1 true KR102374500B1 (ko) 2022-03-15

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167025896A Active KR102374500B1 (ko) 2014-03-31 2015-03-30 바이오프테린 유도체를 포함하는 고체 약제학적 조성물 및 이러한 조성물의 용도

Country Status (28)

Country Link
US (7) US9895372B2 (https=)
EP (2) EP2926805B1 (https=)
JP (3) JP6552515B2 (https=)
KR (1) KR102374500B1 (https=)
CN (2) CN113521017A (https=)
AU (2) AU2015239736B2 (https=)
CA (1) CA2938267C (https=)
CL (1) CL2016002463A1 (https=)
CY (1) CY1117881T1 (https=)
DK (1) DK2926805T3 (https=)
ES (1) ES2586945T3 (https=)
HR (1) HRP20160802T1 (https=)
HU (1) HUE030221T2 (https=)
IL (1) IL248090B (https=)
MX (1) MX377919B (https=)
MY (1) MY180844A (https=)
PE (1) PE20161253A1 (https=)
PH (1) PH12016501519A1 (https=)
PL (1) PL2926805T3 (https=)
PT (1) PT2926805T (https=)
RS (1) RS54973B1 (https=)
RU (1) RU2694368C2 (https=)
SA (1) SA516371933B1 (https=)
SG (1) SG11201606151SA (https=)
SI (1) SI2926805T1 (https=)
SM (1) SMT201600246B (https=)
WO (1) WO2015150294A1 (https=)
ZA (1) ZA201605271B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
PL2926805T3 (pl) 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
JP7811085B2 (ja) * 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
AU2021476139A1 (en) 2021-12-03 2024-05-09 Tibeay Biosciences B.V. Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商ｖｅｒｉＮＯＳ運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084906A1 (en) 2003-03-25 2004-10-07 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
DE59703603D1 (de) 1997-10-06 2001-06-28 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
CA2678125C (en) * 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
AU2005239939C1 (en) * 2004-05-11 2011-06-30 Daiichi Sankyo Company Limited BH4-responsive hyperphenylalaninemia remedies
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
WO2006055511A2 (en) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
WO2008128576A2 (de) 2007-04-24 2008-10-30 Osram Gesellschaft mit beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9006289B2 (en) * 2011-08-30 2015-04-14 Fresenius Kabi Usa, Llc Levothyroxine formulations
PL2926805T3 (pl) 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084906A1 (en) 2003-03-25 2004-10-07 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Also Published As

Publication number Publication date
EP2926805A1 (en) 2015-10-07
KR20160138406A (ko) 2016-12-05
AU2015239736A1 (en) 2016-08-11
US12458644B2 (en) 2025-11-04
US20180289714A1 (en) 2018-10-11
US20200046710A1 (en) 2020-02-13
MX2016012784A (es) 2017-04-25
US10493075B2 (en) 2019-12-03
RU2694368C2 (ru) 2019-07-12
AU2015239736B2 (en) 2020-03-26
PE20161253A1 (es) 2016-11-13
CA2938267C (en) 2023-05-09
ZA201605271B (en) 2017-08-30
CA2938267A1 (en) 2015-10-08
AU2020203880B2 (en) 2022-03-31
HUE030221T2 (en) 2017-04-28
US20260048056A1 (en) 2026-02-19
EP3125864A1 (en) 2017-02-08
ES2586945T3 (es) 2016-10-19
US20210137927A1 (en) 2021-05-13
US11717522B2 (en) 2023-08-08
JP2019194227A (ja) 2019-11-07
SI2926805T1 (sl) 2016-09-30
US10016431B2 (en) 2018-07-10
RU2016141449A (ru) 2018-05-07
NZ722455A (en) 2022-03-25
RS54973B1 (sr) 2016-11-30
CY1117881T1 (el) 2018-03-07
JP6879582B2 (ja) 2021-06-02
US20230355630A1 (en) 2023-11-09
US9895372B2 (en) 2018-02-20
SMT201600246B (it) 2016-08-31
HK1213195A1 (en) 2016-06-30
JP2017509623A (ja) 2017-04-06
PL2926805T3 (pl) 2016-12-30
BR112016020101A2 (https=) 2017-07-15
JP7178731B2 (ja) 2022-11-28
CN113521017A (zh) 2021-10-22
RU2016141449A3 (https=) 2018-12-14
SG11201606151SA (en) 2016-08-30
PH12016501519B1 (en) 2017-02-06
DK2926805T3 (en) 2016-07-25
US20170296543A1 (en) 2017-10-19
US20170112836A1 (en) 2017-04-27
CN106572976A (zh) 2017-04-19
CL2016002463A1 (es) 2017-01-27
JP2021105062A (ja) 2021-07-26
BR112016020101A8 (pt) 2021-06-29
EP2926805B1 (en) 2016-05-18
AU2020203880A1 (en) 2020-07-02
MX377919B (es) 2025-03-10
MY180844A (en) 2020-12-10
IL248090A0 (en) 2016-11-30
JP6552515B2 (ja) 2019-07-31
SA516371933B1 (ar) 2019-04-14
IL248090B (en) 2019-10-31
US20220031703A9 (en) 2022-02-03
PT2926805T (pt) 2016-07-15
PH12016501519A1 (en) 2017-02-06
WO2015150294A1 (en) 2015-10-08
HRP20160802T1 (hr) 2016-08-12
US10925877B2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
US12458644B2 (en) Process for preparing solutions comprising biopterin derivatives
TWI686197B (zh) 包含生物蝶呤衍生物之固體醫藥組合物及該等組合物之用途
HK40056723A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1213195B (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1232799A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112016020101B1 (pt) Composição farmacêutica sólida, composição farmacêutica liofilizada, método para a preparação de uma composição farmacêutica liofilizada sólida, método para a preparação de uma solução injetável e uso da composição farmacêutica
NZ722455B2 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
RU2405554C1 (ru) Средство для лечения туберкулеза

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4